Comparison of Early Clinical Outcomes Following Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement versus Optimal Medical Therapy in Patients Older than 80 Years with Symptomatic Severe Aortic Stenosis by �떊�룞�샇 et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 3   May 2013596
Original Article http://dx.doi.org/10.3349/ymj.2013.54.3.596pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 54(3):596-602, 2013
Comparison of  Early Clinical Outcomes Following  
Transcatheter Aortic Valve Implantation versus Surgical  
Aortic Valve Replacement versus Optimal Medical Therapy  
in Patients Older than 80 Years with Symptomatic  
Severe Aortic Stenosis
Eui Im,1 Myeong-Ki Hong,1,2 Young-Guk Ko,1 Dong-Ho Shin,1 Jung-Sun Kim,1 
Byeong-Keuk Kim,1 Donghoon Choi,1 Chi Young Shim,1 Hyuk-Jae Chang,1 Jae-Kwang Shim,3 
Young-Lan Kwak,3 Sak Lee,4 Byung-Chul Chang,4 and Yangsoo Jang1,2
1Divisions of Cardiology, 3Anesthesiology and Pain Medicine, and 4Cardiovascular Surgery, 
Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul; 
2Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Received: April 25, 2012
Revised: June 27, 2012
Accepted: July 12, 2012
Corresponding author: Dr. Myeong-Ki Hong,
Division of Cardiology, 
Severance Cardiovascular Hospital, 
Yonsei University College of Medicine, 
50 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-8460, Fax: 82-2-2227-7943
E-mail: mkhong61@yuhs.ac
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2013
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: Transcatheter aortic valve implantation (TAVI) has become an attractive 
therapeutic strategy for severe aortic stenosis (AS) in elderly patients due to its 
minimally-invasive nature. Therefore, early results of its clinical outcomes in el-
derly Korean patients were evaluated. Materials and Methods: We compared 
early clinical outcomes of TAVI, surgical aortic valve replacement (SAVR), and 
optimal medical therapy (OMT) in patients aged ≥80 years with symptomatic se-
vere AS. Treatment groups were allocated as follows: TAVI (n=10), SAVR (n=14), 
and OMT (n=42). Results: Baseline clinical characteristics including predicted 
operative mortality were similar among the three groups. However, patients with 
New York Heart Association functional class III or IV symptoms and smaller aor-
tic valve area were treated with TAVI or SAVR rather than OMT. In-hospital com-
bined safety endpoints (all-cause mortality, major stroke, peri-procedural myocar-
dial infarction, life-threatening bleeding, major vascular complication, and acute 
kidney injury) after TAVI or SAVR were significantly lower in the TAVI group 
than in the SAVR group (10.0% vs. 71.4%, respectively, p=0.005), along with an 
acceptable rate of symptom improvement and device success. During the follow-
up period, the TAVI group showed the lowest rate of 3-month major adverse car-
diovascular and cerebrovascular events, a composite of all-cause mortality, myo-
cardial infarction, major stroke, and re-hospitalization (TAVI 0.0% vs. SAVR 
50.0% vs. OMT 42.9%, p=0.017). Conclusion: Treatment with TAVI was associ-
ated with lower event rates compared to SAVR or OMT. Therefore, TAVI may be 
considered as the first therapeutic strategy in selected patients aged ≥80 years with 
symptomatic severe AS.
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combined comorbid disease, physical performance status 
and echocardiographic parameters. Patients were selected 
for TAVI after they were considered as inoperable or high-
risk patients, assessed by two independent cardiovascular 
surgeons. The final treatment groups included 10 patients in 
the TAVI group, 14 in the SAVR group, and 42 in the OMT 
group. 
All 10 TAVI procedures were performed using the Accu-
Trak CoreValve System (Medtronic Inc., Minneapolis, MN, 
USA) under general anesthesia. The prosthetic aortic valve 
was inserted in a retrograde fashion using the femoral artery 
(n=7), subclavian artery (n=1), or ascending aorta (n=2). 
Balloon valvuloplasty was performed prior to prosthetic 
valve deployment. All patients had transvenous temporary 
cardiac pacing during the procedure. Rapid ventricular pac-
ing at 150 to 200 beats/min was performed to reduce cardi-
ac motion and transvalvular flow during balloon dilation. 
Positioning and deployment of the prosthetic valve was 
performed under fluoroscopic guidance. Size 26 mm and 
29 mm prosthetic valves were used. The 26 mm valve was 
selected if the aortic annulus size was 20 to 23 mm (n=6), 
and the 29 mm valve was selected for an aortic annulus size 
of 24 to 27 mm (n=4). Pre-procedural echocardiography 
and multi-slice computed tomography were used to mea-
sure the size of the aortic annulus. Immediately after de-
ployment of the prosthetic valve, transesophageal echocar-
diography was performed to confirm good motion of the 
prosthetic valve and identify any paravalvular leakage. 
We compared in-hospital and 3-month clinical outcomes 
of TAVI, SAVR, and OMT using medical, echocardio-
graphic and angiographic data. Major adverse cardiovascu-
lar and cerebrovascular events (MACCE) during 3-month 
follow-up were defined as a composite of all-cause mortali-
ty, myocardial infarction, major stroke (modified Rankin 
score ≥2), and re-hospitalization due to severe AS or com-
plications of TAVI or SAVR. Definition of each endpoint 
was in accordance with the Valve Academic Research Con-
sortium guidelines.23 Other clinical events including tran-
sient ischemic attack,23 major bleeding, new-onset perma-
nent atrial fibrillation, and complete atrioventricular block 
were also analyzed. Life-threatening bleeding23 or bleeding 
which required blood transfusion24 was considered major 
bleeding. In addition, procedural burden (procedure time 
and length of intensive care unit stay), combined safety end-
points (all-cause mortality, major stroke, peri-procedural 
myocardial infarction, life-threatening bleeding, major vas-
cular complication, and acute kidney injury) according to 
INTRODUCTION
Aortic stenosis (AS) is a progressive disease with a poor 
prognosis if treated medically after symptom onset.1-4 Al-
though surgical aortic valve replacement (SAVR) has been 
shown to improve symptoms and survival,5-7 patients with 
advanced age are at increased risk of surgical complications 
or death.8-10 With aging of the population, the number of 
very old patients with symptomatic severe AS has increased, 
and a significant portion of them are not candidates for 
SAVR because of advanced age and its associated comor-
bidities.11 Therefore, a less invasive treatment strategy is 
desired in such patients. 
Transcatheter aortic valve implantation (TAVI) is a new 
procedure, in which a bioprosthetic valve is inserted through 
a catheter and implanted within the diseased native aortic 
valve. TAVI is a minimally-invasive procedure that avoids 
median sternotomy and the need for cardiopulmonary by-
pass support. After several clinical studies, including the 
pivotal United States placement of aortic transcatheter valve 
trial,12,13 TAVI is now considered as a safe and effective 
treatment modality in elderly patients with symptomatic se-
vere AS.11,14-20
Therefore, this study was performed to compare 3-month 
clinical outcomes of TAVI, SAVR, and optimal medical 
therapy (OMT) in patients aged ≥80 years with symptomat-
ic severe AS.
 
MATERIALS AND METHODS
 
We enrolled 66 consecutive patients aged ≥80 years who 
were newly diagnosed with symptomatic severe AS at our 
institute. Transthoracic echocardiography was used to diag-
nose AS according to the guidelines of the American Soci-
ety of Echocardiography,21 using a digital ultrasound scanner. 
In the apical 5-chamber view, peak and mean transvalvular 
pressure gradient across the aortic valve were calculated us-
ing the Bernoulli equation. The effective aortic valve area 
was calculated using a continuity equation.22 All 66 patients 
exhibited New York Heart Association (NYHA) functional 
class ≥I symptoms, and their echocardiographic findings 
were consistent with severe AS (aortic valve area <1 cm2 
with or without transvalvular mean pressure gradient ≥40 
mm Hg).1 The decision for TAVI or SAVR was made for 
each patient according to the severity of clinical symptoms, 
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comparisons were performed between each two groups. p-
values <0.05 were considered statistically significant.
RESULTS
The baseline clinical and echocardiographic characteristics 
of the three groups are presented in Table 1. More patients in 
the TAVI and SAVR groups exhibited NYHA class III or IV 
symptoms compared to those who were treated with OMT 
(80.0%, 85.7% and 35.7%, p=0.001, respectively). The in-
cidence of pre-existing coronary artery disease was also 
significantly higher in the TAVI and SAVR groups compared 
to the OMT group (70.0%, 57.1% and 19.0%, p=0.001, re-
spectively). Smaller aortic valve area and higher mean trans-
the Valve Academic Research Consortium guidelines,23 and 
procedural efficacy (improvement of clinical symptoms 
and echocardiographic parameters) during hospitalization 
were compared between the TAVI and SAVR groups. Im-
provement of clinical symptoms was defined as at least one 
class improvement in NYHA functional class.
All statistical analyses were performed using Statistical 
Package for Social Sciences (SPSS) statistical software 
package, version 17.0 (SPSS, Chicago, IL, USA). Continu-
ous variables were expressed as a median (interquartile 
range) and compared using Mann-Whitney test or Kruskal-
Wallis test. Categorical variables were described as a num-
ber (%) and analyzed using chi-square test or Fisher’s exact 
test, as appropriate. In case of results with a p-value <0.05 
from the 3-group comparison, three additional pairwise 
Table 1. Baseline Clinical and Echocardiographic Characteristics
Variable TAVI (n=10) SAVR (n=14) OMT (n=42) p value
Clinical variables
    Age (yrs) 82.5 (80.8-85.3) 83.0 (82.8-84.0) 84.0 (81.0-87.0) 0.458
    Men (%)      4 (40.0)      4 (28.6)    19 (45.2) 0.582
    Body mass index (kg/m2) 20.7 (19.2-24.8) 22.3 (20.9-28.7) 21.6 (18.9-23.0) 0.204
    NYHA class III or IV (%)      8 (80.0)*    12 (85.7)*    15 (35.7)† 0.001
    Hypertension (%)      8 (80.0)    10 (71.4)    32 (76.2) 0.918
    Diabetes mellitus (%)      1 (10.0)      4 (28.6)      9 (21.4 ) 0.560
    Coronary artery disease (%)      7 (70.0)*      8 (57.1)*      8 (19.0 )† 0.001
    Previous myocardial infarction (%)      3 (30.0)      1 (7.1)      2 (4.8) 0.064
    Previous cardiac surgery (%)      1 (10.0)      1 (7.1)      2 (4.8) 0.777
    Atrial fibrillation (%)      1 (10.0)      1 (7.1)    12 (28.6) 0.206
    Old cerebrovascular accident (%)      1 (10.0)      2 (14.3)      9 (21.4) 0.725
    Peripheral artery disease (%)      2 (20.0)      1 (7.1)      4 (9.5) 0.523
    Estimated glomerular filtration rate (mL/min/m2)‡ 47.5 (44.0-52.8) 54.5 (46.8-65.8) 51.0 (34.8-67.0) 0.429
    Chronic obstructive pulmonary disease (%)§      5 (50.0)      2 (14.3)      9 (21.4) 0.126
Echocardiographic variables
    Aortic valve area (cm2) 0.60 (0.43-0.72)† 0.58 (0.43-0.71)† 0.78 (0.59-0.88)* 0.005
    Transvalvular mean pressure gradient (mm Hg)    59 (49-70)*    63 (41-83)*    41 (28-53)† 0.001
    Left ventricular ejection fraction (%)    67 (57-71)    61 (38-66)    60 (41-70) 0.407
    Early mitral inflow/mitral annular early diastolic 
      ratio
   21 (15-31)    25 (17-32)    20 (16-35) 0.899
    Left ventricular end-diastolic dimension (mm)    48 (43-53)    47 (45-53)    51 (45-54) 0.854
    Left ventricular end-systolic dimension (mm)    31 (28-36)    34 (30-44)    35 (27-42) 0.591
    Moderate or severe aortic regurgitation (%)      3 (30.0)      2 (14.3)      9 (21.4) 0.623
Predicted operative mortality
    Society of Thoracic Surgeons score (%)   6.9 (6.2-9.1)   5.2 (4.5-11.5)   7.4 (5.7-11.0) 0.275
    Logistic EuroSCORE (%) 24.7 (11.2-36.8) 11.7 (9.0-36.8) 23.4 (15.8-36.6) 0.467
TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; OMT, optimal medical therapy; NYHA, New York Heart Association; 
Logistic EuroSCORE, logistic European System for Cardiac Operative Risk Evaluation.
*,†In case of results with a p-value <0.05 from the 3-group comparison, three additional pairwise comparisons were performed between each two groups. 
Groups with a p-value <0.05 from the pairwise comparisons were labeled with *,†representing the groups with the higher and lower rates, respectively; i.e. 
The comparison between *(higher) vs. †(lower) was significant.
‡Calculated by the modification of diet in renal disease formula.
§Long-term use of bronchodilators or steroids for chronic lung disease, or forced expiratory volume in 1 second <75% of predicted.
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ing hospitalization were compared between the TAVI and 
SAVR groups (Table 4). Compared with the SAVR group, 
the TAVI group showed a lower rate of combined safety 
endpoints (71.4% vs. 10.0%, p=0.005, respectively). 
DISCUSSION
The main finding of the present study is that the TAVI group 
showed the lowest rate of 3-month MACCE when com-
pared to the SAVR and OMT groups in symptomatic pa-
tients aged ≥80 years with severe AS. 
valvular pressure gradient were observed in the TAVI and 
SAVR groups than the OMT group. 
Table 2 shows the 3-month clinical outcomes among the 
three groups. Although there was no statistical difference in 
all-cause mortality among the three groups, no death oc-
curred in the TAVI group, whereas the SAVR group had four 
(28.6%) cases of all-cause mortality and the OMT group 
had nine (21.4%). The rate of 3-month MACCE was signif-
icantly lowest in the TAVI group (0.0% in TAVI vs. 50.0% 
in SAVR vs. 42.9% in OMT, p=0.017). The causes of death 
among the three groups are listed in Table 3.
Additionally, procedural burden, safety, and efficacy dur-
Table 2. Clinical Outcome at 3 Months
Variable TAVI (n=10) SAVR (n=14) OMT (n=42) p value
All-cause mortality 0 (0.0%)   4 (28.6%)   9 (21.4%)   0.190
Myocardial infarction 0 (0.0%)   2 (14.3%) 1 (2.4%)   0.169
Major stroke 0 (0.0%) 1 (7.1%) 1 (2.4%)   0.599
Re-hospitalization* 0 (0.0%)   2 (14.3%)   9 (21.4%)   0.314
Transient ischemic attack 0 (0.0%)    3 (21.4%)†  1 (2.4%)‡   0.043
Stroke or transient ischemic attack 0 (0.0%)    4 (28.6%)†  2 (4.8%)‡   0.033
Major bleeding    1 (10.0%)‡    9 (64.3%)†  4 (9.5%)‡ <0.001
New-onset atrial fibrillation 0 (0.0%)   3 (21.4%) 4 (9.5%)   0.251
Complete atrioventricular block   1 (10.0%)    2 (14.3%)†  0 (0.0%)‡    0.044§
Major adverse cardiovascular and 
  cerebrovascular events
 0 (0.0%)‡    7 (50.0%)†  18 (42.9%)†   0.017
TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; OMT, optimal medical therapy. 
Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, major stroke and re-hospitalization.
*Due to aortic stenosis or complications of TAVI or SAVR. 
†,‡In case of results with a p-value <0.05 from the 3-group comparison, three additional pairwise comparisons were performed between each two groups. 
Groups with a p-value <0.05 from the pairwise comparisons were labeled with †,‡representing the groups with the higher and lower rates, respectively; i.e. 
The comparison between †(higher) vs. ‡(lower) was significant. 
§For complete atrioventricular block, the comparison between SAVR vs. OMT was only marginally significant with p=0.059. 
Table 3. Detailed Causes of Death at 3 Months
Mortality Causes of death
Transcatheter aortic valve implantation (n=10)
    No mortality -
Surgical aortic valve replacement (n=14)
    Mortality 1 Post-operative bleeding
    Mortality 2 Peri-operative myocardial infarction due to coronary embolism
    Mortality 3 Acute kidney injury due to massive gastrointestinal bleeding
    Mortality 4 Acute kidney injury due to massive gastrointestinal bleeding
Optimal medical therapy (n=42)
    Mortality 1 Acute myocardial infarction
    Mortality 2 Sudden cardiac death due to ventricular fibrillation
    Mortality 3 Sudden cardiac death due to ventricular fibrillation
    Mortality 4 Decompensated heart failure
    Mortality 5 Decompensated heart failure
    Mortality 6 Decompensated heart failure
    Mortality 7 Decompensated heart failure
    Mortality 8 Septic shock due to community acquired pneumonia
    Mortality 9 Septic shock due to community acquired pneumonia
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pressure gradient <75 mm Hg was as low as 20%. Similar-
ly, in the present study, the rate of SAVR was 21.2% (14 of 
66 patients), and patients with more severe symptom of dys-
pnea, smaller aortic valve area, and greater transvalvular 
mean pressure gradient inevitably underwent SAVR. 
Facing this dilemma between the need for surgery and 
the high surgical mortality rate in patients aged ≥80 years, 
TAVI with minimally-invasive nature could be an attractive 
alternative treatment modality. With proven safety and effi-
cacy,11-20 more patients aged ≥80 years who would have been 
candidates for SAVR are now undergoing TAVI. Like the 
SAVR group, patients with more severe symptom of dys-
pnea, higher incidence of pre-existing coronary artery dis-
ease, smaller aortic valve area, and greater transvalvular 
mean pressure gradient underwent TAVI in this study. 
The other main finding of the present study is that TAVI 
had a lower rate of in-hospital combined safety endpoints 
than SAVR. This was mainly due to a lower rate of in-hospi-
tal all-cause mortality and life-threatening bleeding in TAVI 
than in SAVR. Previous publications report that a 30-day 
mortality rate after TAVI ranges from 3.2% to 15.2%.12-20,27,28 
Although the mean age was over 80 years in these previous 
studies, some of the patients were under 80 years. In the 
present study, in-hospital all-cause mortality rate of TAVI 
was 0.0%, even though all patients were over the age of 80. 
The excellent mortality outcomes of TAVI may be due to 
meticulous patient selection, pre-procedural planning, or 
post-procedural care in strict compliance with recommen-
The prognosis in patients with symptomatic severe AS is 
poor if treated medically.1-4 After symptom onset, the 1-year 
mortality rate in patients with severe AS and without SAVR 
is reportedly around 30%.2,4 Moreover, one could easily ex-
pect a higher mortality rate in the patients of the present 
study, aged ≥80 years, than those of previous studies,2,4 even 
though there are no available published data regarding the 
prognosis of medically treated patients in the selected popu-
lations. This was also confirmed in the present study with a 
reported 3-month mortality rate of 21.4% in the OMT group. 
SAVR is the treatment of choice for patients with symp-
tomatic severe AS.1 However, the risk of surgical mortality 
increases significantly with age.8-10 Although early mortality 
rate of combined valve and coronary bypass surgery was 
low in some reports,25 in-hospital mortality of SAVR with 
concomitant coronary bypass surgery has been reported as 
high as 24% in patients aged ≥80 years.9 In the present study, 
the in-hospital mortality rate of SAVR was 28.6%. Because 
of these high surgical mortality rates, surgeons sometimes 
hesitate to perform SAVR in patients aged ≥80 years, or pa-
tients themselves are reluctant to undergo SAVR in real-
world clinical practice. Therefore, SAVR is occasionally re-
served only for patients with very small aortic valve area or 
high transvalvular pressure gradient whose clinical symp-
toms are not stabilized by OMT alone. In a previous study 
by Bouma, et al.,26 the actual rate of SAVR in patients aged 
≥80 years was only 23.8%. In addition, the surgery rate in 
patients with NYHA class I/II dyspnea or transvalvular peak 
Table 4. Procedural Burden, Safety, and Efficacy of TAVI and SAVR during Hospitalization
Variable TAVI (n=10) SAVR (n=14) p value
Procedural burden
    Procedure time (mins)   135 (98-172)   278 (238-320) 0.001
    Intensive care unit stay (days) 4 (3-5) 7 (3-50) 0.225
Safety endpoints
    All-cause mortality    0 (0.0%)    4 (28.6%) 0.114 
    Major stroke    0 (0.0%)  1 (7.1%) 1.000 
    Peri-procedural myocardial infarction    0 (0.0%)    2 (14.3%) 0.493 
    Life-threatening bleeding      1 (10.0%)    7 (50.0%) 0.079 
    Major vascular complications    0 (0.0%)  0 (0.0%) -
    Acute kidney injury    0 (0.0%)    4 (28.6%) 0.114 
    Combined safety endpoints      1 (10.0%)  10 (71.4%) 0.005 
Procedural efficacy
    Symptom improvement in New York Heart 
      Association functional class
     8 (80.0%)    9 (64.3%) 0.653 
    Aortic valve area >1.2 cm2      9 (90.0%)  13 (92.9%) 1.000 
    Transvalvular mean pressure gradient <20 mm Hg      9 (90.0%)  12 (85.7%) 1.000 
    Moderate prosthetic valve aortic regurgitation      1 (10.0%)  0 (0.0%) 0.417 
TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement.
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